MSF calls for broader access to ERVEBO vaccine during Ebola outbreak
Marie Sembu, a nurse with the Congolese Ministry of Health, prepares an ERVEBO vaccine injection during the launch event for the BRAVO study at the Bunia Provincial Public Health Laboratory. | DR Congo 2026 © Kristen Poels/MSF
Cases and health response
As the Bundibugyo Ebola outbreak continues in Democratic Republic of Congo (DRC), /Médecins Sans Frontières (MSF) is calling for access to ERVEBO, the only licensed Ebola vaccine currently available at scale, to be expanded rapidly.
MSF is urging the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) to lift restrictions limiting ERVEBO vaccination to research protocols so that available doses can be deployed rapidly to protect those most at risk.
MSF is also calling for enough doses to be made available to support a meaningful expansion of vaccination. ERVEBO is not an experimental vaccine.
It is currently authorized for use in individuals aged 1 year and older.
Outbreak background
It is licensed and approved for use against Ebola disease caused by Ebola virus (but not the Bundibugyo virus causing the current outbreak) and has a well-established safety profile from previous Ebola responses in DRC.
